Disease · MONDO_0020249
Drugs13
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 13 of 13
Download this page as JSON| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| EPOETIN BETA | CHEMBL2109092 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| AFLIBERCEPT | CHEMBL1742982 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CLEMASTINE | CHEMBL1626 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METFORMIN | CHEMBL1431 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TEPROTUMUMAB | CHEMBL1743079 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | CHEMBL2108981 | Phase 1 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets | |
| CENEGERMIN | CHEMBL4297852 | Protein | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INSULIN HUMAN | CHEMBL1201631 | Protein | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RANIBIZUMAB | CHEMBL1201825 | Antibody | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TIMOLOL MALEATE | CHEMBL1200870 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0020249/drugs